Related references
Note: Only part of the references are listed.Predictors of Kidney Tubular Dysfunction in HIV-Infected Patients Treated with Tenofovir: A Pharmacogenetic Study
Sonia Rodriguez-Novoa et al.
CLINICAL INFECTIOUS DISEASES (2009)
Tenofovir renal safety in HIV-infected patients: Results from the SCOLTA project
Giordano Madeddu et al.
BIOMEDICINE & PHARMACOTHERAPY (2008)
Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HN-Infected patients
Jennifer J. Kiser et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2008)
Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy
Miguel Goicoechea et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
Rosiglitazone reverses tenofovir-induced nephrotoxicity
Alexandre B. Liborio et al.
KIDNEY INTERNATIONAL (2008)
The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients
J. J. Kiser et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Transport of a fluorescent cAMP analog in teleost proximal tubules
Valeska Reichel et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2007)
The private sector and HIV/AIDS in Africa: taking stock of 6 years of applied research
Sydney Rosen et al.
AIDS (2007)
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years
Mark R. Nelson et al.
AIDS (2007)
Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2)
Yuichi Uwai et al.
PHARMACEUTICAL RESEARCH (2007)
Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors
Johanna Weiss et al.
DRUG METABOLISM AND DISPOSITION (2007)
Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir
Tomoki Imaoka et al.
MOLECULAR PHARMACOLOGY (2007)
Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy
Hassane Izzedine et al.
JOURNAL OF INFECTIOUS DISEASES (2006)
Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir
Brian P. Kearney et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2006)
Mechanism of active renal tubular efflux of tenofovir
Adrian S. Ray et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Evaluation of hypophosphataemia in tenofovir disoproxil fumarate (TDF)-exposed and TDF-unexposed HIV-infected out-patients receiving highly active antiretroviral therapy
K. Buchacz et al.
HIV MEDICINE (2006)
Mortality in the highly active antiretroviral therapy era - Changing causes of death and disease in the HIV outpatient study
Frank J. Palella et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2006)
Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: A pilot study
Peter L. Anderson et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2006)
Hemochromatosis (HFE) gene mutations and peripheral neuropathy during antiretroviral therapy
Asha R. Kallianpur et al.
AIDS (2006)
96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures
M Johnson et al.
AIDS (2006)
Human renal organic anion transporters: Characteristics and contributions to drug and drug metabolite excretion
EE Robertson et al.
PHARMACOLOGY & THERAPEUTICS (2006)
Tenofovir-associated acute and chronic kidney disease: A case of multiple drug interactions
AE Zimmermann et al.
CLINICAL INFECTIOUS DISEASES (2006)
Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia
M Rotger et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
Multidrug resistance-associated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition of tenofovir disoproxil fumarate and its metabolites
R Mallants et al.
XENOBIOTICA (2005)
Functional consequences of single nucleotide polymorphisms in the human organic anion transporter hOAT1 (SLC22A6)
K Bleasby et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects
S Rodriguez-Novoa et al.
CLINICAL INFECTIOUS DISEASES (2005)
Antiviral drug-induced nephrotoxicity
H Izzedine et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2005)
Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites
RAMH Van Aubel et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2005)
Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts
AM Martin et al.
AIDS (2005)
Antiretroviral therapy with tenofovir is associated with mild renal dysfunction
S Mauss et al.
AIDS (2005)
Tenofovir-related nephrotoxicity in HIV-infected patients
A Barrios et al.
AIDS (2004)
Role of purine nucleoside phosphorylase in interactions between 2′,3′-dideoxyinosine and allopurinol, ganciclovir, or tenofovir
AS Ray et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Renal tubular dysfunction associated with tenofovir therapy -: Report of 7 cases
H Peyrière et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2004)
Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure
BS Rifkin et al.
AMERICAN JOURNAL OF MEDICINE (2004)
The role of CFTR and SPINK-1 mutations in pancreatic disorders in HIV-positive patients:: a case-control study
C Felley et al.
AIDS (2004)
Down-regulation of Na+ transporters and AQP2 is responsible for acyclovir-induced polyuria and hypophosphatemia
L Andrade et al.
KIDNEY INTERNATIONAL (2004)
Tenofovir disoproxil fumarate - Clinical pharmacology and pharmacokinetics
BP Kearney et al.
CLINICAL PHARMACOKINETICS (2004)
Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques
KKA Van Rompay et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome:: The role of lopinavir-ritonavir-didanosine
F Rollot et al.
CLINICAL INFECTIOUS DISEASES (2003)
Tumour necrosis factor-alpha gene-238G/A promoter polymorphism associated with a more rapid onset of lipodystrophy
D Nolan et al.
AIDS (2003)
Fanconi syndrome and renal failure induced by tenofovir: A first case report
D Verhelst et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2002)
Rapid communication: Acute renal failure associated with tenofovir: Evidence of drug-induced nephrotoxicity
S Coca et al.
AMERICAN JOURNAL OF THE MEDICAL SCIENCES (2002)
Intestinal absorption enhancement of the ester prodrug tenofovir disoproxil fumarate through modulation of the biochemical barrier by defined ester mixtures
J van Gelder et al.
DRUG METABOLISM AND DISPOSITION (2002)
Polymorphisms in the ABCC2 (cMOAT/MRP2) gene found in 72 established cell lines derived from Japanese individuals:: An association between single nucleotide polymorphisms in the 5′-untranslated region and exon 28
M Itoda et al.
DRUG METABOLISM AND DISPOSITION (2002)
Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors
T Cihlar et al.
ANTIVIRAL RESEARCH (2002)
Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir
S Mallal et al.
LANCET (2002)
Assessment of mitochondrial toxicity in human cells treated with tenofovir: Comparison with other nucleoside reverse transcriptase inhibitors
G Birkus et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults
P Barditch-Crovo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2001)
Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects
S Ito et al.
PHARMACOGENETICS (2001)
Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs
T Cihlar et al.
NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS (2001)
Share Paper
